LEADER 03740nam 2200601Ia 450 001 9910438131403321 005 20200520144314.0 010 $a1-283-61254-2 010 $a9786613924995 010 $a1-4614-4021-1 024 7 $a10.1007/978-1-4614-4021-5 035 $a(CKB)2670000000245983 035 $a(EBL)973533 035 $a(OCoLC)809369322 035 $a(SSID)ssj0000738581 035 $a(PQKBManifestationID)11433129 035 $a(PQKBTitleCode)TC0000738581 035 $a(PQKBWorkID)10792903 035 $a(PQKB)10796983 035 $a(DE-He213)978-1-4614-4021-5 035 $a(MiAaPQ)EBC973533 035 $a(PPN)168299054 035 $a(EXLCZ)992670000000245983 100 $a20120921d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNuclear medicine therapy $eprinciples and clinical applications /$fCumali Aktolun, Stanley J. Goldsmith, editors 205 $a1st ed. 2013. 210 $aNew York $cSpringer$d2012 215 $a1 online resource (444 p.) 300 $aDescription based upon print version of record. 311 $a1-4614-4020-3 320 $aIncludes bibliographical references and index. 327 $aLymphoma -- Leukemia -- Myeloproliferative Neoplasms -- Neuroendocrine Tumors -- Bone Metastases and Bone Pain -- Melanoma -- Brain Tumors -- Well Differentiated ThyroidCarcinomas -- Medullary Carcinoma of Thyroid -- Breast Carcinoma -- Liver Tumors-Radiomicrosphere Therapy -- Liver Tumors-Systemic Radionuclide Therapy -- Colo-rectal Carcinoma -- Pancreatic Carcinoma -- Renal Cell Carcinoma -- Prostate Carcinoma -- Radioiodine Therapy of Benign Thyroid Diseases -- Radiosynoviorthesis -- Chemistry of Therapeutic Radiopharmaceuticals -- Pretargeting: Advancing the Delivery of Therapeutic Radionuclides -- Radiobiology and Low Dose Rate Radiation Effects -- Radiation Safety Considerations for Radionuclide Therapy -- Challenges Associated with Radionuclide Therapy. 330 $aNuclear Medicine Therapy presents the state of the art in targeted radionuclide therapy, both in clinical practice and contemporary clinical investigation and trials. With contributions from an internationally-distinguished group of physicians and scientists, the book is devoted entirely to the use of nuclear medicine techniques and technology for therapy of malignant and benign diseases. Individual chapters cover the scientific principles and clinical applications of radionuclide therapy and the state of clinical trials of agents currently under investigation in the therapy of tumors involving virtually every organ system. Due to overlapping interest in techniques, indications, and clinical use, the development of radionuclide therapy attracts considerable input from other medical specialists whose collaboration is essential, including radiation and medical oncologists, hematologists, diagnostic radiologists, hepatologists, endocrinologists, and rheumatologists. And because radionuclide therapy is a rapidly evolving field of nuclear medicine, it is the aim of this volume to appeal to all specialists involved in targeted radionuclide therapy and to contribute to the standardization of the practice globally. 606 $aRadioisotopes$xTherapeutic use 606 $aNuclear medicine 615 0$aRadioisotopes$xTherapeutic use. 615 0$aNuclear medicine. 676 $a615.8 676 $a615.8424 701 $aAktolun$b Cumali$01755258 701 $aGoldsmith$b Stanley J$01755259 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910438131403321 996 $aNuclear medicine therapy$94191981 997 $aUNINA